Govindan named Anheuser-Busch Endowed Chair in Medical Oncology

Ramaswamy Govindan, MD, has been named the Anheuser-Busch Endowed Chair in Medical Oncology at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

The Anheuser-Busch Foundation established the endowed chair in 2001 through The Foundation for Barnes-Jewish Hospital. Govindan was honored for his innovative research, including in genomics, aimed at developing better lung cancer therapies and improving patient outcomes.

“This represents what is so right about academic medicine at Washington University School of Medicine,” said David H. Perlmutter, MD, dean of the School of Medicine and executive vice chancellor for medical affairs. “We are recognizing a member of our faculty who is a former trainee. This academic medical center has an unbelievably rich tradition of graduating its trainees to prominent positions in academic medicine here, across the country and internationally.”

Govindan, who completed his fellowship in hematology/oncology at the School of Medicine in 1996, was named chief of the Section of Medical Oncology at the School in 2015. He was co-director from 2010 to 2015. He sees lung cancer patients at Siteman Cancer Center, where Washington University physicians are developing new therapies and leading clinical trials that investigate promising new approaches to the disease.

Elsewhere on the research side, Govindan is a co-chair of the lung cancer group for The Cancer Genome Atlas project, a national effort to describe the genomic alterations of common cancers. He also leads a national clinical trial called ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) that screens tumors from lung cancer patients and assigns treatments based on the molecular alterations in patients’ tumors.

Victoria J. Fraser, MD, the Adolphus Busch Professor of Medicine and head of the Department of Medicine, said even though she has treated patients for 30 years, she has learned from Govindan’s bedside manner.

“I know this personally because he took care of my mother,” Fraser said. “We were without hope; everyone was devastated. Dr. Govindan coming into the room just made us all feel better.

“He sat down next to my mother, made sure his head and eyes were lower than hers. He took both her hands in his and told her he would take care of her, that no matter what he would be there for her and for all of us. And he was.”

Bob Cannon, president of Barnes-Jewish Hospital and group president of BJC HealthCare, said Govindan’s research leadership helps develop “better standards of care and better outcomes for patients in St. Louis and around the world.

“In addition, we recognize his dedication to sharing his knowledge and expertise with future generations of exceptional physician-researchers,” Cannon said.

Govindan earned his medical degree at the University of Madras in his native India. He has been a member of Washington University’s faculty since 1998. He completed his residency in internal medicine at Jawaharlal Institute of Postgraduate Medical Education and Research, also in India, followed by an internship and residency in internal medicine at Michael Reese Hospital and Medical Center in Chicago and a fellowship in hematology and oncology at Washington University.

Since 1997, Anheuser-Busch and the Anheuser-Busch Foundation have contributed more than $515 million to charitable organizations, including those that support education, medicine, the environment, economic development, disaster relief and military personnel.

Goodman appointed to City of St. Louis Board of Health and Hospitals​

Melody Goodman, PhD, has been appointed to the City of St. Louis Board of Health and Hospitals.

Melody Goodman, PhD, an assistant professor of surgery at Washington University School of Medicine and a research member of Siteman Cancer Center, has been appointed to the City of St. Louis Board of Health and Hospitals.

Mayor Francis Slay appointed Goodman, who will serve until 2019. In the role, she will advise the city health commissioner on public health matters.

“I am honored to be appointed to the Board of Health by Mayor Slay,” Goodman said. “This is a great opportunity to share what I am learning in my community-engaged public health research to help guide those doing public health practice.”

A biostatistician in the Division of Public Health Sciences at the School of Medicine, Goodman researches the origins of health disparities, especially in the St. Louis region. She develops evidence-based primary prevention strategies to reduce these health disparities. Goodman’s work has been instrumental in enhancing the infrastructure for community-academic partnerships and increasing the role of minority and medically underserved communities in research.

Mardis visits White House to discuss​​ cancer research​

Elaine Mardis, PhD, co-director of The McDonnell Genome Institute at Washington University School of Medicine in St. Louis, joined a group of 14 other distinguished cancer researchers and physician-scientists Jan. 8 at the White House to talk with Vice President Joseph Biden’s staff about his “moonshot” challenge to cure cancer.

The researchers, convened by the American Association for Cancer Research (AACR), highlighted precision medicine, immunotherapy and other advances against the disease.

“I was really honored to be part of the group of cancer researchers and clinicians invited to discuss these critically important ideas with the vice president’s staff,” said Mardis, who is the Robert E. and Louise F. Dunn Distinguished Professor of Medicine. She also is a member of the AACR Board of Directors and a research member of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

Biden, who lost a son to cancer last year, has called for a “national commitment” to end the disease. “And I’m going to spend the next 15 months in this office pushing as hard as I can to accomplish this,” he said in October.

In President Barack Obama’s State of the Union address Jan. 12, Obama said Biden would lead a historic push to find a cure for cancer. He said Biden would be in charge of “mission control” for the effort.

Biden’s staff and the scientists who met with them Jan. 8 discussed AACR initiatives including Project GENIE (Genomics, Evidence, Neoplasia, Information, Exchange), which aims to aid clinical decision-making by linking the genetic profiles of tumors with clinical outcomes.

The visit came after a separate meeting with Food and Drug Administration staff members about next-generation genome sequencing, laboratory-developed tests and diagnostics.

“It’s a very exciting time with the advances being made against cancer,” Mardis said. “By working with our government officials, this progress will continue in a manner that is conducted in the best interests of cancer patients.”​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​